Rare germline mutations in multiple genes (BRCA1, BRCA2, ATM, PALB2, CDH1, TP53, FANCM, CHEK2, MLH1, MSH2, MSH6 and PMS2) are known to be associated with increased breast and/or ovarian cancer susceptibility and these genes are included in most commercial gene panel tests for breast and ovarian cancer susceptibility [2]. The gene discussed is MSH2; the disease is ovarian carcinoma.